Cargando…

Evaluation of Lymphovascular Invasion by CD31 Expression in Gastric Adenocarcinoma

BACKGROUND & OBJECTIVE: Lymphovascular tumoral invasion is a typical histopathological feature of gastric carcinomas and supports the recognition of high-risk patients for the recurrence. We aimed to study CD31 expression in diverse subtypes of gastric carcinomas and to show its association with...

Descripción completa

Detalles Bibliográficos
Autores principales: Miratashi Yazdi, Seyed Amir, Nazar, Elham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iranian Society of Pathology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439755/
https://www.ncbi.nlm.nih.gov/pubmed/37600573
http://dx.doi.org/10.30699/ijp.2023.562466.2977
Descripción
Sumario:BACKGROUND & OBJECTIVE: Lymphovascular tumoral invasion is a typical histopathological feature of gastric carcinomas and supports the recognition of high-risk patients for the recurrence. We aimed to study CD31 expression in diverse subtypes of gastric carcinomas and to show its association with the histopathologic findings of the carcinoma to assess the prognosis. METHODS: This cross-sectional study was conducted on 40 established patients with gastric adenocarcinoma from radical gastrectomy. The patients were classified according to the pathology assessments. Tumoral tissues were assessed by immunohistochemical staining for CD31 expression. Malignant behavior was estimated by histopathological evaluations. RESULTS: CD31 positivity was described in 23 (57.5%) of all evaluated patients. In assessment of CD31 expression and tumor features presented, no significant association between the CD31 expression and patients’ age, sex, tumor site, size, grade and stage, subtypes of carcinoma, perineural invasion, and also lymphovascular invasion was found. (P>0.05). CONCLUSION: Lymphovascular invasion may make valuable additional evidence and may be useful to detect gastric carcinoma patients at high risk for recurrence, who could be candidates for more supplementary therapies. However, in our study, CD31 expression did not show any association with the aggressive histopathologic features of this tumor.